Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target

por Schulz-Heddergott, Ramona, Moll, Ute M.
Publicado 2018

CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan

por Blume, Joshua, Claus, Luisa, Isermann, Tamara, Dickmanns, Antje, Conradi, Lena-Christin, Schulz-Heddergott, Ramona, Dobbelstein, Matthias
Publicado 2023

p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo

por Alexandrova, Evguenia M, Mirza, Safia A, Xu, Sulan, Schulz-Heddergott, Ramona, Marchenko, Natalia D, Moll, Ute M
Publicado 2017

The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells

por Klemke, Luisa, Fehlau, Clara F., Winkler, Nadine, Toboll, Felicia, Singh, Shiv K., Moll, Ute M., Schulz-Heddergott, Ramona
Publicado 2021

Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer

por Klemke, Luisa, De Oliveira, Tiago, Witt, Daria, Winkler, Nadine, Bohnenberger, Hanibal, Bucala, Richard, Conradi, Lena-Christin, Schulz-Heddergott, Ramona
Publicado 2021

Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity

por Isermann, Tamara, Şener, Özge Çiçek, Stender, Adrian, Klemke, Luisa, Winkler, Nadine, Neesse, Albrecht, Li, Jinyu, Wegwitz, Florian, Moll, Ute M., Schulz-Heddergott, Ramona
Publicado 2021

The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53

por Piqué-Borràs, Maria-Riera, Jevtic, Zivojin, Bagger, Frederik Otzen, Seguin, Jonathan, Sivalingam, Rathick, Bezerra, Matheus Filgueira, Louwagie, Amber, Juge, Sabine, Nellas, Ioannis, Ivanek, Robert, Tzankov, Alexandar, Moll, Ute M., Cantillo, Oriano, Schulz-Heddergott, Ramona, Fagnan, Alexandre, Mercher, Thomas, Schwaller, Juerg
Publicado 2023